Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCTR
- Development stage
- Unknown
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
OCTR is a bispecific antibody (BsmAb) designed for retargeted T cell-mediated lysis, primarily investigated for advanced ovarian carcinoma. It functions by simultaneously binding to the CD3 receptor on T cells and the folate receptor expressed on ovarian carcinoma cells. This dual targeting mechanism aims to redirect the patient's own T cells to specifically recognize and destroy cancer cells, offering a novel therapeutic approach for patients who have relapsed after induction chemotherapy.
02
Targets
CD3 (T-cell surface glycoprotein CD3)FOLR1 (FRα)
Beyond the preview
Go deeper on OCTR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OCTR.